| Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca |
- Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - |
globenewswire.com |
2024-12-24 11:30:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market |
LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. |
globenewswire.com |
2024-11-19 09:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports Third Quarter 2024 Financial Results |
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 – |
globenewswire.com |
2024-11-14 09:00:00 |
Czytaj oryginał (ang.) |
| Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? |
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year. |
zacks.com |
2024-09-23 14:47:33 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Announces Strategic Update |
–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials. |
globenewswire.com |
2024-09-19 11:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates |
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – |
globenewswire.com |
2024-08-14 11:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines |
Research collaboration combines Achilles' best-in-class AI-driven, tumor-targeting technology with Arcturus' world-leading self-amplifying mRNA platform |
globenewswire.com |
2024-05-22 11:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement |
Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice |
globenewswire.com |
2024-05-17 21:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights |
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. “Just after the close of the first quarter, we shared the interim Phase I/IIa data from our ongoing CHIRON and THETIS TIL-based cNeT clinical trials which have given us important mechanistic learnings about the factors driving durable engraftment and immune evasion at an antigen level. |
globenewswire.com |
2024-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights |
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights. “In 2023, we made important progress on the optimization of our VELOS™ manufacturing process with a significant improvement in cNeT doses delivered and are developing our understanding of the relationship between host conditioning and the engraftment of infused cNeT. |
globenewswire.com |
2024-04-04 10:45:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning |
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer (NSCLC) and the THETIS study in recurrent or metastatic malignant melanoma. The update includes data from 18 patients across CHIRON (n=12) and THETIS (n=6) dosed since the previous interim update in December 2022, with two CHIRON patients and one THETIS patient having received enhanced chemo-conditioning and IL-2 dosing aligned to standard tumor infiltrating lymphocyte (TIL) therapy (enhanced host conditioning) in a new Cohort C. |
globenewswire.com |
2024-04-04 10:30:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference |
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: |
globenewswire.com |
2024-02-05 09:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment' on Strategy for Improved Neoantigen Immunogenicity Prediction |
Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies |
globenewswire.com |
2023-12-18 09:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights |
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 – – Strong cash position of $140 million supports operations through 2025 – LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. “We are pleased with progress across the scientific field that continues to demonstrate the importance of neoantigens as the most attractive targets in solid-tumor oncology. |
globenewswire.com |
2023-11-13 18:30:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement |
- Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice - - Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company's operations are not affected by the receipt of the Notice - |
globenewswire.com |
2023-09-22 20:30:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year? |
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and HealthEquity (HQY) have performed compared to their sector so far this year. |
zacks.com |
2023-09-22 15:16:53 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights |
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - |
globenewswire.com |
2023-08-04 11:00:00 |
Czytaj oryginał (ang.) |
| Achilles Therapeutics to Present at Upcoming Conferences |
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: |
globenewswire.com |
2023-06-12 12:00:00 |
Czytaj oryginał (ang.) |
| 3 Stocks With 1,000% Upside Potential |
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high. |
investorplace.com |
2023-05-21 14:03:52 |
Czytaj oryginał (ang.) |
| Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year? |
Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year. |
zacks.com |
2023-02-02 13:18:40 |
Czytaj oryginał (ang.) |